Stargardt Disease clinical trials

Explore recruiting stargardt disease clinical trials.

Recruiting stargardt disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Stargardt Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects

France, Netherlands, Belgium, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label, Single-Arm, 3-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Subjects with Stargardt Disease

Netherlands, France, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2, First-in-Human, Open-label, Assessor-Masked, Randomized, Controlled, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects with Stargardt Disease (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ATP Binding Cassette Subfamily A Member 4 (ABCA4) Gene (ASTRA).

Germany, Belgium

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

An Open-label, Multicenter, Two Part, Ascending Dose Followed by a Controlled Trial to Assess the Safety and Efficacy of a Subretinal Administration of AAVB-039 in Participants with Stargardt Disease (STGD1) (CELESTE)

Belgium, Italy, Netherlands, Norway

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Stargardt Disease trials by city

Stargardt Disease in Toronto Stargardt Disease in Vancouver Stargardt Disease in Montreal Stargardt Disease in Calgary Stargardt Disease in Edmonton Stargardt Disease in Ottawa Stargardt Disease in Winnipeg Stargardt Disease in Quebec City Stargardt Disease in Hamilton Stargardt Disease in Kitchener Stargardt Disease in London Stargardt Disease in Halifax Stargardt Disease in New York Stargardt Disease in Los Angeles Stargardt Disease in Chicago Stargardt Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease